@article{ca07a14c9b9d4d57b8704b442de9868f,
title = "Global Access for Biologics in the Treatment of Severe Asthma: A Challenge to Personalized Medicine",
abstract = "Rationale: Four different classes of monoclonal antibodies have been approved for use in severe asthma: anti-IgE (omalizumab), anti-IL-5 (mepolizumab, reslizumab), anti-IL-5Rα (benralizumab), and anti-IL-4/IL-13 (dupilumab)",
author = "A. Menzies-Gow and T.N. Tran and N. Hossein and N. Eleangovan and M. Rowlands and L. Bulathsinhala and Mark Hew and Upham, {J. W} and Heaney, {L. G} and C. Ulrik and D. Larenas-Linnemann and J. Boven and FitzGerald, {J. M.} and M. Alacqua and E. Wang and M. Al-Ahmad and Cosio, {B. G.} and D.J. Jackson and {Perez de Llano}, L. and C. Porsbjerg and Rasmussen, {L. M.} and J. Schmid and A. Papaioannou and Stelios Loukides and M. Kallieri and N. Lugogo and A. Tan and I. Chaudhry and V. Carter and R. Murray and Price, {D. B.}",
note = "This abstract is funded by: ISAR is conducted by Optimum Patient Care Global Limited, and co-funded by OPC Global and AstraZeneca",
year = "2020",
doi = "10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A5954",
language = "English",
volume = "201",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society - AJRCCM",
number = "C93",
}